|Day Low/High||15.00 / 15.70|
|52 Wk Low/High||9.70 / 27.50|
4 stocks on my shopping list for when conditions improve.
Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Sangamo Therapeutics Inc . The average 12-month price target for SGMO — averaging the work of 6 analysts — reveals an average price target of $23.50/share.
The market's reaction to James Bullard's comments this morning is following an all-too-common pattern.
Kite, a Gilead Company (Nasdaq:GILD) and Sangamo Therapeutics, Inc.
-- Kite to Receive Exclusive License to Leverage Sangamo's Gene Editing Technology in Allogeneic and Autologous Cell Therapy Programs in Oncology --
Here's what you need to know now for Wednesday, Feb. 14.
It's hard to believe the bounce will continue to run in V-shaped fashion.
It is a very different market environment now which can be very rewarding depending on your style.
If we have a little consolidating action here the buyers will start pushing again.
There are signs of stabilization, but the market is still digesting some very big swings.
The volatility trade that propped up markets is no longer available.
It would be a longer-term positive if the overbought conditions are alleviated.
What drives the trading action are structural issues, not macroeconomic news events or political drama.
There is still a very strong appetite for individual stocks with momentum.
If you're looking for something negative to say about this action about the only thing you might argue is that the action is too positive.
Investors in Sangamo Therapeutics Inc saw new options become available this week, for the August 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
I'm trying not to be sucked into the market-timing game and am looking mainly at setups in individual stocks.
But you need to be selective and have discipline.
In recent trading, shares of Sangamo Therapeutics Inc have crossed above the average analyst 12-month target price of $15.50, changing hands for $16.20/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
We have shifted from a market that was mainly index driven by the FAANG names to one where stock picking is more important.
Jim Cramer is bullish on Delta Air Lines, BioTelemetry, TransUnion, Amgen and Littelfuse.
Jim Cramer says there's a case to be made for underpricing, even in this market.
The Boston firm said microbiology data show that investigational antibiotic omadacycline is 'active against the clinically important typical and atypical community-acquired bacterial pneumonia (CABP) pathogens.'
I've cut a few positions and haven't made any notable buys today.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.